1. Blum, R. H.: An overview of studies with Adriamycin (NSC 123127) in the United States. Cancer Chemother. Rep., 6: 247–251, 1975.
2. O’Bryan, R. M., Baker, L. H., Gottlieb, J. E., Rivkin, S. E., Balcerzak, S. P., Grumet, G. N., Salmon, S. E., Moon, T. E. and Hoogstraten, B.: Dose response evaluation of Adriamycin in human neoplasia. Cancer, 39: 1940–1948, 1977.
3. Schoenfeld, D. A., Rosenbaum, C., Horton, J., Wolter, J. M., Falkson, G. and DeConti, R. C: A comparison of Adriamycin versus vincristine and Adriamycin, and cyclophosphamide versus vincristine, actinomycin D, and cyclophosphamide for advanced sarcoma. Cancer, 50: 2757–2762, 1982.
4. Bramwell, V. H. C., Mouridsen, H. T., Mulder, J. H., Somers, R., Van Oosterom, A. T., San-toro, A., Thomas, D., Sylvester, R., Markham, D.: Carminomycin vs. adriamycin in advanced soft tissue sarcomas; an EORTC randomized phase II study. Eur. J. Cancer Clin. Oncol. 19: 1097–1104, 1983.
5. Mouridsen, H. T., Somers, R., Santoro, A., Mulder, J. H., Bramwell, V., Van Oosterom, A. T., Sylvester, R., Thomas, D., Pinedo, H. M.: Doxorubicin vs epirubicin in advanced soft tissue sarcomas. An EORTC randomized phase II study. In: Advances in anthracycline chemotherapy: Epirubicin, edited by Bonadonna, G., Masson Milano, 95–103, 1984.